No Data
No Data
We're Not Very Worried About Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Rate
Companies Like Mineralys Therapeutics (NASDAQ:MLYS) Are In A Position To Invest In Growth
Mineralys Therapeutics Completes Target Enrollment In Pivotal Advance-HTN Trial Of Lorundrostat For The Treatment Of Hypertension
Mineralys Therapeutics Hits Enrollment Milestone in Hypertension Trial
Express News | Mineralys Therapeutics Inc - Expects to Announce Topline Data in Q1 2025
Express News | Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-Htn Trial of Lorundrostat for the Treatment of Hypertension